ASX biotech timelines

Good news today from an under-the-radar Aussie biotech. And unlike Starpharma, they delivered today on schedule. It really is about time that Jackie Fairley start under-promising and over-delivering if that’s at all possible.

The 16 years of CEO Jackie Fairley shifting goal posts, ghosted partnerships, delayed trials and shifting timelines is beyond the pale. Shareholders deserve so much more.

This is how it’s done:

Dec 2021
Neuren (NEU) announce positive top-line results from a pivotal Phase 3 trial in Rett syndrome. The CEO tells shareholders that their US partner Acadia plans to submit a New Drug Application (NDA) to the FDA around mid-year 2022.

Today (19 July 2022) Acadia submits the Rett Syndrome New Drug Application to the FDA.

Whereas this is how things go for SPL:

July 2018
CEO Fairley in an interview says the Phase 2 DEP-Docetaxel trial is expected to be completed within 6 months. STILL WAITING

Dec 2018
FDA says no to VivaGel BV in the USA. CEO Fairley tells shareholders that Starpharma is looking for a resolution as quickly as possible. STILL WAITING

Feb 2021
In an interview with Alan Kohler, CEO Fairley tells shareholders that TGA regulatory approval of Viraleze should only be a “matter of weeks”. STILL WAITING

June 2021
CEO Fairley says Starpharma is also in discussion with multiple other sporting teams (after Harlequins) interested in using the Viraleze to keep their players and athletes safe. STILL WAITING

June 2021
CEO Fairley says commercial discussions with commercial partners in India for distribution of Viraleze into both the private (consumer) and Government markets are well advanced. STILL WAITING

There are many many many other examples but I just can’t be bothered.

P.S. Happy to be a shareholder of a company that actually delivers on what they promise. Any other examples?

P.S. It is still my humble opinion that Starpharma will be removed from the ASX300 in the next rebalance coming soon.

DYOR